Parallax Volatility Advisers’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$14.4M Sell
300,000
-15,600
-5% -$670K 0.02% 331
2026
Q1
$12.4M Buy
315,600
+22,900
+8% +$1.09M 0.03% 354
2025
Q4
$14.9M Sell
292,700
-134,900
-32% -$6.9M 0.03% 364
2025
Q3
$23.7M Buy
427,600
+172,500
+68% +$10.1M 0.04% 262
2025
Q2
$17.6M Sell
255,100
-8,200
-3% -$558K 0.04% 299
2025
Q1
$18.3M Buy
263,300
+35,000
+15% +$2.89M 0.05% 293
2024
Q4
$19.6M Buy
228,300
+18,700
+9% +$2.02M 0.04% 345
2024
Q3
$25M Buy
209,600
+88,000
+72% +$11.7M 0.05% 280
2024
Q2
$17.4M Buy
121,600
+82,500
+211% +$10.9M 0.04% 326
2024
Q1
$5.02M Buy
+39,100
New +$4.65M 0.01% 732
2023
Q3
Sell
-141,000
Closed -$11.4M 2508
2023
Q2
$11.4M Buy
+141,000
New +$11.5M 0.02% 496

Other funds holding NVO

Parallax Volatility Advisers's NVO Position: Q2 2026 in Review

Parallax Volatility Advisers sold out of Novo Nordisk (NVO) in Q2 2026, closing a stake of 11,936 shares — an estimated $513K sold.

Parallax Volatility Advisers first reported a position in NVO in Q1 2018 and held it in 17 quarters. The position peaked at $12.1M in Q3 2024. 1,355 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Parallax Volatility Advisers reported no remaining Novo Nordisk position as of Q2 2026 after selling out during the quarter.
  • Parallax Volatility Advisers sold 11,936 Novo Nordisk shares in Q2 2026, an estimated $513K.
  • Parallax Volatility Advisers first reported a position in Novo Nordisk in Q1 2018 and held it in 17 quarters.
  • Parallax Volatility Advisers's Novo Nordisk position peaked at $12.1M in Q3 2024.
  • 1,355 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Parallax Volatility Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.